FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3123960236> ?p ?o ?g. }

• W3123960236 endingPage "1019" @default.
• W3123960236 startingPage "1013" @default.
• W3123960236 abstract "Objective: To explore dasatinib-related pulmonary adverse events in patients with chronic myeloid leukemia (CML) . Methods: We retrospectively analyzed the incidence of pleural effusion (PE) and pulmonary arterial hypertension (PAH) in patients with CML treated with dasatinib at Peking University People's Hospital from April 2008 to January 2020. Results: A total of 280 patients were collected. The median dasatinib treatment time was 26 (1-142) months. Ninety (32.1%) patients developed PE, including 40 (44.4%) in grade 1, 44 (48.9%) in grade 2, and 6 (6.7%) in grade 3. The incidence of PE increased gradually with the prolongation of treatment. The multivariate analysis showed that increasing age (every 10 years, HR=1.6; P<0.001) , advanced phase when starting dasatinib therapy (HR=2.2; P=0.008) , and cardiovascular comorbidity (ies) (HR=1.9; P=0.018) were significantly associated with developing PE. The advanced phase when starting dasatinib therapy (HR=3.4; P=0.001) , interval from diagnosis to taking TKI for ≤6 months (HR=2.2; P=0.015) , and dose < 100 mg/d when PE was found (HR=3.1; P=0.001) were associated with more severe PE. PE relieved or disappeared after intervention in half of the patients. Among 60 patients with symptoms of cough, chest tightness, and shortness of breath, 49 underwent ultrasonic cardiography; 8 (16.3%) had high probability of PAH, approximately 3.5% in all patients; and 6 (75.0%) of them had PE. PAH was reversible. There was no difference in the incidences of PE and PAH between branded and Chinese generic dasatinib. Conclusion: PE is a common dasatinib-related pulmonary adverse event, and PAH is rare in patients with CML. The identification of individuals with high risk, close monitoring, and timely intervention may help to alleviate PE and PAH." @default.
• W3123960236 created "2021-02-01" @default.
• W3123960236 creator A5019415924 @default.
• W3123960236 creator A5037029781 @default.
• W3123960236 creator A5041912669 @default.
• W3123960236 creator A5047273213 @default.
• W3123960236 creator A5052596963 @default.
• W3123960236 creator A5071438551 @default.
• W3123960236 creator A5084153398 @default.
• W3123960236 date "2020-12-14" @default.
• W3123960236 modified "2023-09-26" @default.
• W3123960236 title "[Dasatinib-related pulmonary adverse events in patients with chronic myeloid leukemia]." @default.
• W3123960236 cites W2007790016 @default.
• W3123960236 cites W2043694799 @default.
• W3123960236 cites W2051389077 @default.
• W3123960236 cites W2070507117 @default.
• W3123960236 cites W2126579741 @default.
• W3123960236 cites W2166654361 @default.
• W3123960236 cites W2171620938 @default.
• W3123960236 cites W2319904066 @default.
• W3123960236 cites W2397234997 @default.
• W3123960236 cites W2406641958 @default.
• W3123960236 cites W2414352770 @default.
• W3123960236 cites W2496712281 @default.
• W3123960236 cites W2520429294 @default.
• W3123960236 cites W2521911861 @default.
• W3123960236 cites W2529873314 @default.
• W3123960236 cites W2604779344 @default.
• W3123960236 cites W2757003661 @default.
• W3123960236 cites W2784092116 @default.
• W3123960236 cites W2886320425 @default.
• W3123960236 cites W2891716460 @default.
• W3123960236 cites W2891981936 @default.
• W3123960236 cites W3009751715 @default.
• W3123960236 doi "https://doi.org/10.3760/cma.j.issn.0253-2727.2020.12.008" @default.
• W3123960236 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7840556" @default.
• W3123960236 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33445849" @default.
• W3123960236 hasPublicationYear "2020" @default.
• W3123960236 type Work @default.
• W3123960236 sameAs 3123960236 @default.
• W3123960236 citedByCount "0" @default.
• W3123960236 crossrefType "journal-article" @default.
• W3123960236 hasAuthorship W3123960236A5019415924 @default.
• W3123960236 hasAuthorship W3123960236A5037029781 @default.
• W3123960236 hasAuthorship W3123960236A5041912669 @default.
• W3123960236 hasAuthorship W3123960236A5047273213 @default.
• W3123960236 hasAuthorship W3123960236A5052596963 @default.
• W3123960236 hasAuthorship W3123960236A5071438551 @default.
• W3123960236 hasAuthorship W3123960236A5084153398 @default.
• W3123960236 hasConcept C120665830 @default.
• W3123960236 hasConcept C121332964 @default.
• W3123960236 hasConcept C126322002 @default.
• W3123960236 hasConcept C141071460 @default.
• W3123960236 hasConcept C197934379 @default.
• W3123960236 hasConcept C2777583451 @default.
• W3123960236 hasConcept C2778729363 @default.
• W3123960236 hasConcept C2779536868 @default.
• W3123960236 hasConcept C2779634585 @default.
• W3123960236 hasConcept C61511704 @default.
• W3123960236 hasConcept C71924100 @default.
• W3123960236 hasConcept C90924648 @default.
• W3123960236 hasConceptScore W3123960236C120665830 @default.
• W3123960236 hasConceptScore W3123960236C121332964 @default.
• W3123960236 hasConceptScore W3123960236C126322002 @default.
• W3123960236 hasConceptScore W3123960236C141071460 @default.
• W3123960236 hasConceptScore W3123960236C197934379 @default.
• W3123960236 hasConceptScore W3123960236C2777583451 @default.
• W3123960236 hasConceptScore W3123960236C2778729363 @default.
• W3123960236 hasConceptScore W3123960236C2779536868 @default.
• W3123960236 hasConceptScore W3123960236C2779634585 @default.
• W3123960236 hasConceptScore W3123960236C61511704 @default.
• W3123960236 hasConceptScore W3123960236C71924100 @default.
• W3123960236 hasConceptScore W3123960236C90924648 @default.
• W3123960236 hasIssue "12" @default.
• W3123960236 hasLocation W31239602361 @default.
• W3123960236 hasOpenAccess W3123960236 @default.
• W3123960236 hasPrimaryLocation W31239602361 @default.
• W3123960236 hasRelatedWork W1868909663 @default.
• W3123960236 hasRelatedWork W2010901133 @default.
• W3123960236 hasRelatedWork W2051389077 @default.
• W3123960236 hasRelatedWork W2077663268 @default.
• W3123960236 hasRelatedWork W2088026712 @default.
• W3123960236 hasRelatedWork W2149797825 @default.
• W3123960236 hasRelatedWork W2394724078 @default.
• W3123960236 hasRelatedWork W2414030522 @default.
• W3123960236 hasRelatedWork W2466389266 @default.
• W3123960236 hasRelatedWork W2549865882 @default.
• W3123960236 hasRelatedWork W2556547291 @default.
• W3123960236 hasRelatedWork W2558133906 @default.
• W3123960236 hasRelatedWork W2560411042 @default.
• W3123960236 hasRelatedWork W2564629313 @default.
• W3123960236 hasRelatedWork W2604779344 @default.
• W3123960236 hasRelatedWork W2757003661 @default.
• W3123960236 hasRelatedWork W2886320425 @default.
• W3123960236 hasRelatedWork W2891981936 @default.
• W3123960236 hasRelatedWork W2968511180 @default.
• W3123960236 hasRelatedWork W2979425209 @default.
• W3123960236 hasVolume "41" @default.

• next